Patents by Inventor Bin YOO

Bin YOO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
    Patent number: 12600776
    Abstract: The present invention relates to an anti-L1CAM antibody specifically binding to L1CAM antigen or an antigen-binding fragment thereof, a chimeric antigen receptor comprising same, and uses thereof. The anti-L1CAM antibody or the antigen-binding fragment of the present invention is excellent in specificity and affinity to L1CAM and thus may be used in the treatment and diagnosis of cancers related to high expression of L1CAM and diseases related to inflammatory disorders. In particular, when the chimeric antigen receptor comprising the anti-L1CAM antibody of the present invention is expressed in effector cells such as T lymphocytes, the chimeric antigen receptor may be effectively used as immunotherapy for cancers related to L1CAM and inflammatory disorders.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: April 14, 2026
    Assignee: CARTEXELL INC.
    Inventors: Jin-A Chae, Jae-Gyun Jeong, Dae Young Kim, Yu Jung Kim, Bin Yoo
  • ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME
    Publication number: 20220242948
    Abstract: The present invention relates to an anti-L1CAM antibody specifically binding to L1CAM antigen or an antigen-binding fragment thereof, a chimeric antigen receptor comprising same, and uses thereof. The anti-L1CAM antibody or the antigen-binding fragment of the present invention is excellent in specificity and affinity to L1CAM and thus may be used in the treatment and diagnosis of cancers related to high expression of L1CAM and diseases related to inflammatory disorders. In particular, when the chimeric antigen receptor comprising the anti-L1CAM antibody of the present invention is expressed in effector cells such as T lymphocytes, the chimeric antigen receptor may be effectively used as immunotherapy for cancers related to L1CAM and inflammatory disorders.
    Type: Application
    Filed: October 21, 2019
    Publication date: August 4, 2022
    Inventors: Jin-A CHAE, Jae-Gyun JEONG, Dae Young KIM, Yu Jung KIM, Bin YOO